Teva Pharmaceutical Industries Ltd. has seen a lot of exit and entry of investors. The likes of
IFM Investors Pty Ltd,
Assenagon Asset Management S.A.,
Amundi,
Gateway Investment Advisers LLC,
Ion Asset Management Ltd.,
Cutter Capital Management LP and
Intech Investment Management LLC have increased their holdings while others such as
Voya Investment Management LLC,
Tri Locum Partners LP,
First Manhattan CO. LLC,
Alyeska Investment Group L.P., and
Wellington Management Group LLP have reduced their stakes.
EVP McAvoy and another
top executive also purchased the company's shares. Major banks like
UBS,
Goldman Sachs,
JPMorgan,
Piper Sandler and
BofA upgraded and reiterated the company's buy rating.
UBS has raised the price target of Teva's stock to $26. The company's stock has surged in multiple instances due to several reasons such as positive clinical results, the launch of generic
Saxenda,
FDA Approvals and new venture outcomes. It recently saw a dip, however, due to the narrowing of full-year guidance post beating
Q2 earnings.
Teva Pharmaceutical Stocks News Analytics from Wed, 06 Nov 2024 08:00:00 GMT to Thu, 25 Sep 2025 21:32:17 GMT -
Rating 5
- Innovation -3
- Information 7
- Rumor 2
